Articol

Systemic therapy for atopic dermatitis

Systemic therapy for atopic dermatitis

Systemic therapy for atopic dermatitis (AD) is indicated in patients with severe disease refractory to adequate topical treatment. Currently available drugs aim to decrease inflammation by suppressing and/or modulating immune responses and thus may indirectly improve skin barrier function


Systemic therapy for atopic dermatitis

 

D. Simon1 & T. Bieber

Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; 2Department of Dermatology and Allergy, University of Bonn, Bonn, Germany

 

Abstract

 

Systemic therapy for atopic dermatitis (AD) is indicated in patients with severe disease refractory to adequate topical treatment. Currently available drugs aim to decrease inflammation by suppressing and/or modulating immune responses and thus may indirectly improve skin barrier function, resulting in a decrease in clinical signs and symptoms in particular pruritus. Before considering systemic treatment, patient adherence to topical treatment including skin care has to be ensured. The selection of the drug depends on the disease severity, localization, complications, concomitant diseases, and age of the patient, but also on their availability and costs as well as the doctor’s experience. Bearing in mind the potential risk of resistance, systemic therapy with antibiotics should be exclusively considered in clinically man- ifest infections such as in children. Here, we review recently published clinical trials and case reports on systemic therapy of pediatric and adult patients with AD to draw conclusions for clinical practice. Although AD is a common disease, con- trolled clinical studies investigating the efficacy of systemic drugs are scarce, except for cyclosporine, which has been approved for the therapy of severe AD.

 

Atopic dermatitis (AD) is the most common skin disease in childhood with an impressive increase in the prevalence over the last decades (1–4). Although AD may disappear  over  time, 40–60% of pediatric patients with  AD  continue  to  have symptoms later on in life (5, 6). Although in approxi- mately 60% of patients AD manifests in childhood, it may  also develop in adolescent and  adults (6). Fortunately, most   of the patients with AD can control their skin disease with topical therapy and skin care. However, there is a consider- able group of patients with severe AD who have eczematous skin lesions not responding to the prescribed treatment with moisturizers, topical corticosteroids (TCS), and/or topical calcineurin inhibitors (TCI) or experience immediate flare-  ups after tapering  topical  anti-inflammatory  therapy.  In  cases of refractory AD, it is important to check whether the diagnosis of AD is correct and consider possible differential diagnoses (e.g., allergic or irritant contact dermatitis, psoria- sis, cutaneous mycosis, scabies, cutaneous T-cell lymphoma, or even genetic disorders such as Netherton syndrome, hyper-IgE syndrome, and Wiskott–Aldrich syndrome). In particular, contact allergies to ingredients of  topical  drugs,  for example, to preservatives, emollients, fragrances, and corticosteroids, have to be excluded (7, 8). Most  impor-  tantly, the compliance of the patients or  their  parents  is  a real issue.

The success of any, in particular topical dermatological ther- apy, depends on the patient’s adherence. To achieve a maximal effect, the treatment should individually be tailored to the patient’s needs, such as skin condition with special focus on severity of skin lesions, affected areas, skin dryness, and prefer- ence of vehicles, and consider avoidance of triggering factors, for example, allergens, skin irritants, and psychological stress. In our experience, refractory AD is not always due to ineffec- tiveness or tachyphylaxis to topical therapy, but rather an issue of compliance. Individual treatment plans, patient education, including basic knowledge on the pathogenesis, practical dem- onstrations, and written instructions are a prerequisite for improving compliance. By application of wet wraps, the effect of medications or moisturizers can be enhanced and a rapid reduction in pruritus may be achieved (9). Wet wraps are suit- able for use at home, for localized and generalized skin lesions in particular for short-term intervention of acute flares in pedi- atric and adult patients. In our experience, education and prac- tical demonstrations given by an experienced nurse in the eczema clinics significantly increase patient compliance.

 

When should systemic therapy be considered?

 

If AD cannot be controlled by topical therapy despite opti- mizing treatment plan and adherence, systemic therapy should be considered (10, 11). Patients with severe AD are mainly those with early onset, widespread/generalized skin lesions, and long and continuous disease course. Short-term systemic therapy with immunosuppressive drugs should also be discussed in patients with acute severe exacerbations. In addition, severe localized AD lesions might call for systemic therapy. Atopic lid eczema and blepharoconjunctivitis often require systemic immunosuppressive intervention to prevent secondary alterations of the lids  and  ectropium.  Hand  eczema that often follows a chronic disease course has a high impact  on  patients’  quality  of  life  due  to  inflammation  and pruritus as well as restrictions in  occupational  and  private activities. Therefore, in addition to avoiding irritants and contact allergens, the decision on systemic therapy, for example, with alitretinoin for hand eczema, should not be protracted.

Systemic immunosuppressive therapy for concomitant ato- pic diseases, for example, bronchial asthma, often results in a simultaneous improvement in AD lesions. In children with severe AD, systemic immunosuppressive therapy should be considered to allow age-appropriate physical and psychic growth and prevent complications such as hypoproteinemia resulting in growth retardation and behavioral deficits as well as improve patients’ and their families’ quality of life (12– 14). In addition to the objective clinical signs of AD, the decision on systemic therapy is strongly dictated by subjective symptoms and the patient’s complains, in particular pruritus followed by scratching, secondary restlessness and sleepless- ness, anxiety about uncertain disease course, and complica- tions as well as fear of adverse effects of topical  drugs,  namely TCS (15). Further, individual life situations, for example, customer contact, final examinations, and jobless- ness (often triggered by AD), might force to initiate more potent therapeutic measures.

Before starting any immunosuppressive or immunomodula- tory therapy for AD, a clinical  and  laboratory  work-up  of  the patient is mandatory. In particular, underlying active infectious diseases including hepatitis B and C or HIV infec- tions have to be ruled out. Necessary organ function tests before and during therapy depend on the drugs prescribed.

 

Which options are available for the systemic therapy of AD?

 

Pathogenic background

 

Recent progress in understanding the pathogenesis of AD revealed its heterogeneity based on the distinct genetic and epigenetic profiles as well as various pathophysiological path- ways involved. This heterogeneity results in various endophe- notypes and subsequently distinct clinical phenotypes  (16).  So far, AD phenotypes have mainly been distinguished based on clinical presentation, severity, onset and disease  course, IgE sensitization, and concomitant allergic diseases. Accord- ing to our current knowledge, AD results from complex gene–gene and gene–environment interactions (17–19). Genes relevant for AD pathogenesis have been assigned to genes involved in the epidermal barrier function and genes involved in the regulation of innate and adaptive  immune  responses (16, 20, 21). An impaired skin barrier, for example, caused    by missing or reduced expression and/or function of filaggrin (22, 23), LEKTI (24) or antimicrobial peptides (25) making  the skin susceptible for environmental irritant, microbial and allergenic factors may give rise to an inflammatory reaction involving both innate and adaptive immune responses (26– 30). The resulting skin inflammation is dominated by a T- helper 2 response (17), which itself may further impair skin barrier function (31, 32).

Considering these pathogenic events as key factors in AD development implies that the treatment has to focus on the restoration of the impaired skin barrier and the resolution of skin inflammation as well as the avoidance of environmental triggers (33). Even though systemic immunosuppressive ther- apy may effectively reduce cellular infiltration and cytokine expression, the remaining two therapeutic aims should not be neglected to achieve maximal improvement and avoid exacer- bations of AD.

 

Immunosuppressive and immunomodulatory therapy

 

Systemic therapy for AD currently stands for immunosup- pressive and immunomodulatory therapy as systemic drugs effectively restoring skin barrier function are not  available  yet. Substances such as cyclosporine, azathioprine, myco- phenolate mofetil, and methotrexate reduce disease-relevant inflammatory cell numbers and cytokine expression, but also exert general immunosuppressive effects (34). Alitretinoin, interferon, intravenous immunoglobulins, and  biologics  can be ascribed to immunomodulatory substances that  may  restore immune balance (Fig. 1).

 

Corticosteroids

 

By binding to regulatory elements of many genes via their receptor, glucocorticosteroids affect the transcription of sev- eral mediators involved in the pathogenesis of AD including cytokines, chemokines, and adhesion molecules by inflamma- tory cells as well as resident cells. This results in an inhibi-  tion of cell proliferation, vasoconstriction, and resolution of inflammation (34). Therapy with oral corticosteroids should  be restricted to break severe exacerbations of AD and pruri- tus. Controlled clinical trials in both children and adults are lacking. As a rule, the initial dosage  of  0.75–1  mg/kg  per day should be tapered in 7–10 days.  Methylprednisolone  bolus therapy (intravenous; 20 mg/kg per  day  for  3  days) was reported to achieve a fast and sustained  improvement  over several weeks in 5 of 7 children (35). In adults  with severe AD, oral  prednisolone  (0.5–0.8  mg/kg  per  day)  for  2 weeks was not able to sufficiently control symptoms (36). Therefore, despite their frequent use in daily praxis, oral corticosteroids are not recommended to induce stable remis- sion of AD or long-term control because of potential side- effects. These include diabetes, hypertension, gastric ulcers, osteoporosis, skin atrophy, glaucoma, Cushing’s syndrome, and growth  retardation.  As  patients  often  develop  a rebound effect after tapering, ceasing oral corticosteroids  might be challenging.

 

Cyclosporine

 

Cyclosporine  inhibits  T-cell  activation  and   proliferation   by blocking nuclear factor of activated T cells (NFAT)- dependent cytokine production (34). In randomized placebo- controlled trials, cyclosporine has been demonstrated to have significant beneficial effects in improving skin lesions, pruri- tus, and thus quality of life in adult  and  pediatric  patients with AD (37–39).

A meta-analysis of 15 studies,  including  over  600  patients, revealed  55%  improvement  in  disease  severity after 6–8 weeks of cyclosporine treatment  (40).  Cyclospor- ine is licensed for the treatment of severe AD in some European countries. Doses of 3–5 mg/kg body  weight  per  day are recommended for initial therapy, which can  be  tapered after achieving improvement of  AD.  In  most  patients, a short-term therapy is  sufficient.  It  can  be  repeated in patients with recurrent flare-ups (interval ther-  apy) (41). Patients with chronic severe AD and frequent exacerbations might require long-term therapy with an indi- vidually adjusted maintenance dose at lowest levels control- ling the disease (41).

In any cases, concomitant topical corticosteroid therapy  may be needed, but is well tolerated and might decrease the minimum effective dose of cyclosporine (40). Due to poten-

 tial adverse effects, in particular renal toxicity and hyperten-sion,   monitoring   of   renal   function   parameters   and blood pressure is mandatory (41). Adverse events appeared more likely in patients treated with higher doses (40).  Because  of an increased risk for skin cancer, cyclosporine therapy should not be combined with phototherapy.

 

Azathioprine

 

Azathioprine, which blocks the synthesis of RNA and DNA and thus inhibits the proliferation of T and B cells, has been used for treatment of severe AD for years in particular in the UK and USA (34). Studies in children and adults supplied evidence for its efficacy in improving skin symptoms, reduc- ing pruritus and sleep loss, decreasing Staphylococci coloni- zation (42–46). Azathioprine may cause severe side-effects including gastrointestinal disturbances, liver dysfunction, and leukopenia (45). The underlying cause for myelosuppressive effects of azathioprine is a partial or total deficiency in thiop- urine methyltransferase (TPMT) activity. Patients at risk can be identified by determining TPMT activity and/or genotyp- ing. In children screened for normal TPMT levels before therapy, no myelosuppression was observed under treatment with 2.5–3.5 mg/kg azathioprine for severe AD (47). Adult patients with AD, in whom the  azathioprine  dose  was adapted to TPMT activity, showed similar disease improve- ment compared with patients with normal TPMT activity receiving 2.5 mg/kg azathioprine (48).

 

Mycophenolic acid

 

The efficacy of mycophenolate mofetil (MMF) in the treat- ment for severe AD has been shown in several  cases  and small studies (49–54). Monotherapy with MMF with initial doses of 1 g twice daily over 4 weeks followed by 4 weeks with 0.5 g twice daily lead to a significant reduction in dis- ease severity with a sustained improvement during the follow-up until week 20 (49). The percentage of patients responding to MMF therapy can be estimated with 70–80% (50, 51). Successful long-term treatment in three patients with MMF 1–2 g daily over 12 to 29 months has been reported  (52). After inducing remission with high-dose cyclosporine, maintenance therapy with mycophenolate sodium (1440 mg/ day) was as effective as low-dose cyclosporine in improving signs and symptoms of AD (55). Main adverse  events  reported under mycophenolic acid therapy in patients  with  AD were nausea, fatigue, flu-like symptoms, liver enzyme abnormalities, and infections such as herpes zoster, herpes simplex, and staphylococcal infection (50, 51, 55, 56).

 

Methotrexate

 

Methotrexate is an analogue of folic acid interfering with folic acid metabolism, resulting in a reduced production of pyrimi- dine and purine nucleotides required for DNA and RNA synthesis. Thus, methotrexate may reduce chemotaxis of and cytokine production by lymphocytes or induce cell death (34). Methotrexate was shown to be effective in moderate-to-severe AD. The application of a median dose of 15 mg per week resulted in a decrease in disease activity by 52% from baseline after 24 weeks with a persistent improvement in 8 of 12 patients over 12 weeks after stopping therapy (57). A retro- spective study reported an improvement of >70% as assessed by the physician in 75% of patients treated with weekly doses of 7.5 to 25 mg methotrexate intramuscularly over 3 months (58). Similar results were achieved by low-dose methotrexate therapy with 10–25 mg weekly for 8 to 12 weeks (59). Note that, it takes approximately 2 weeks to 3 months after initiat- ing therapy until symptoms improve (57–59). Patients not responding to 15 mg methotrexate per week after  three  months failed to improve with further dose escalation (57). A recent study reported that methotrexate 7.5 mg per week is as effective and safe as cyclosporine 2.5 mg/day in children with severe AD at age 7–14 years (60). Before starting methotrexate therapy, liver toxicity and teratogenicity have to be consid- ered. Nausea and increase in liver enzymes were the main adverse events observed that eventually caused transient or total discontinuation of methotrexate therapy (58–60).

 

Alitretinoin

 

Alitretinoin, 9-cis retinoic acid, is an antagonist vitamin A derivate that binds to both retinoic acid receptors RAR and RXR. Alitretinoin has been shown to be effective in the treatment for severe hand eczema, including atopic hand eczema (61). Best responses were observed in hyperkeratotic forms and fingertip eczema (61, 62). Recently, it is has been reported that alitretinoin at a standard dose of 30 mg daily significantly improved extra-palmar AD lesions in six patients treated for severe atopic hand eczema (63). As hand eczema severely affects patients’ quality of life, treatment with alitre- tinoin should be considered in AD patients with involvement of the hands not responding to topical corticosteroids and/or calcineurin inhibitors. Most frequent adverse effects reported were headache, increase in serum cholesterol and triglyceride levels, and decrease in thyroid-stimulating hormone (61). As all retinoids are teratogenic, alitretinoin is not indicated in pregnant women, and treatment of women  at  childbearing  age should be avoided or given under strict contraception.

 

Intravenous immunoglobulins

 

Because of their immunomodulatory potential, intravenous immunoglobulins (IVIg) have been used for the treatment of severe autoimmune and inflammatory skin diseases including severe AD (34). First observations on  an  improvement  in  AD skin symptoms were made in patients treated with intra- venous gamma-globulins for Kawasaki disease or idiopathic thrombocytopenic purpura, who had AD in addition (64). Adjunctive therapy with IVIg (six cycles with high-dose IVIg  2 g/kg per month) significantly improved skin symptoms in four of six patients with AD (65). Moreover, IVIg therapy allowed the reduction in concomitant systemic drugs in patients on long-term corticosteroid therapy (66). The benefit of IVIg therapy for patients with severe AD has controver- sially been discussed, as some reports revealed no or just  slight improvement (67, 68). IVIgs have also been used in children with severe AD (three cycles of 2 g/kg IVIg per month), resulting in a significant decrease in disease activity and inflammatory markers, for example, serum eosinophil cationic protein levels (69). In a recent case series, a decrease in blood eosinophilia and IgE levels in parallel with an allevi- ation of skin symptoms has been reported following  IVIg  (70). In children with AD refractory to systemic immunosup- pressive therapy, IVIg should be considered (71).

 

Interferon-gamma

 

Although mentioned in certain guidelines and reviews, inter- feron (rIFN)-gamma therapy became less important, most likely because of alternative drugs with better benefit–risk profiles.

Treatment with  recombinant  interferon  (rIFN)-gamma leads to a normalization of  the  cytokine  dysbalance  in AD by decreasing IL-4 and IL-6 (72). Best results in controlling AD symptoms have been achieved with an induction of remission followed by a maintenance therapy with IFN- gamma up to 2 years (73–75). Long-term IFN-gamma ther- apy has successfully been administered to children (76). The main adverse effects reported were flu-like symptoms (74).

 

Biologics

 

Biologics have widely been used in dermatology, in particular for the treatment of psoriasis and autoimmune  diseases. So  far, none of the biologics available has been approved for AD therapy. Several biologics that have the potential to target cytokines or mediators known to play a role in the pathogene- sis of AD have been used in individual patients and small clin- ical trials. Some of these reports were summarized here.

 

 

Anti-CD20

 

The depletion of B cells, known to act as antigen-presenting cells, promote T-cell activation and produce proinflammatory cytokines and IgE, with rituximab (anti-CD20 antibody) resulted in a rapid reduction in skin inflammation in all  patients with a sustained effect over 5 months in five of six patients, although specific IgE levels were  not affected (77).  In two cases affected by very severe AD, rituximab showed limited effects (78).

 

Anti-IL-5

 

Skin inflammation of AD is associated with eosinophilic infil- tration. Therefore, depletion of eosinophils seems a promis-  ing approach for AD treatment. Upon  short-term  therapy  with an anti-IL-5 antibody (mepolizumab; 2 9 750 mg), a moderate improvement in clinical symptoms was observed,

although a rapid depletion of eosinophils in the peripheral blood was noted (79). Studies investigating a reduction in exacerbations and steroid-sparing effect of anti-IL-5 antibody therapy in AD analogous to those performed in patients with bronchial asthma (80, 81) have not been performed so far.

 

Anti-IgE

 

Based on the observations that approximately  80%  of  patients with AD have increased IgE levels in blood, anti-IgE antibody therapy has been applied. Upon low-dose anti-IgE antibody therapy (omalizumab, 10 cycles of 150 mg), SCO- RAD levels decreased by 50% in two and by 25–50% in four of 11 patients with AD (82). A significant improvement in  skin symptoms has been reported in patients with concomi- tant AD and bronchial asthma receiving omalizumab because of severe airway disease (83). Interestingly, a randomized placebo-controlled double-blind study revealed no significant effect of omalizumab on clinical signs of AD, although a decrease in serum IgE levels, surface IgE, and FceRI receptor expression on blood cells as well as a reduction in IgE+ cells but not FceRI+ cells in the skin was observed (84). A recent study identified AD patients with wild-type filaggrin  status and higher serum levels of phosphatidylcholines as respond- ers to omalizumab therapy (85). Meanwhile, omalizumab therapy in combination with IVIg and rituximab has been applied to patients with severe AD resulting in drastic clinical improvement and long-term effects (86, 87).

 

 

      

Anti-TNF-a and other strategies

 

Anti-TNF-alpha therapy has been reported to significantly decrease AD signs and symptoms including pruritus during induction therapy, but failed to achieve a long-term mainte- nance effect (88). However, inadequate effects or even severe exacerbations of AD  upon  anti-TNF-alpha  therapy  have been reported (89, 90). Therefore, we would not recommend this treatment for AD.

Blocking the IL-6 receptor pathway resulted in a marked improvement in AD in severely affected  patients, however, led to adverse severe infections (91).

Considering the pathogenesis of AD,  there  are  a number  of interesting mediators and receptors that might serve as potential therapeutic targets, for example, IL-4, IL-13, and their receptors, as well as IL-25, IL-31, histamine, and hista- mine receptors 1 and 4 (92, 93).

 

Immunoabsorption

 

Based on the observation that a subgroup of patients with severe AD has extremely increased total serum IgE levels,

immunoabsorption was applied. A  pilot  study  investigating 12 patients with  AD refractory to systemic treatment showed  a 24% to 82% individual SCORAD reduction upon ten immunoabsorptions (94). In parallel, skin-bound IgE and inflammatory cell numbers decreased, whereas only a short- term depletion of serum IgE was observed (94). So far, ran- domized trials on immunoabsorption are not available and long-term effects are not known.

 

 

Allergen-specific immunotherapy

 

Although allergen-specific immunotherapy (ASIT) has widely been applied for other atopic diseases such as allergic rhinitis and asthma, the number of studies in AD is limited. ASIT     has mainly been studied in patients with AD sensitized to house dust mites and birch pollen. Both subcutaneous and sublingual applications have been applied. After 1 year of ASIT to house dust mites, a decrease in AD severity and concomitant topical corticosteroid use in a dose-dependent manner was observed (95). In particular, patients with severe AD were reported to profit from ASIT to house dust mites  (96). Also, SLIT results in a significant improvement in AD   as assessed by SCORAD in patients with AD sensitized to house dust mites (97). Some patients with AD allergic to pol- len experience acute exacerbations during pollen seasons. ASIT with birch pollen extract for 12 weeks was shown to significantly reduce skin symptoms and improve  quality  of life despite strong birch pollen exposure (98). Although a recent systematic review on ASIT for AD stated a significant positive effect (99), current data do not allow a broad recom- mendation so far.

 

 

Antimicrobial treatment

Antibiotics

 

The impaired skin barrier predisposes for microbial coloniza- tion on lesional as well as nonlesional skin, for example, with Staphylococcus  aureus  in  over  90%  of  patients  with  AD.

S. aureus can trigger exacerbations and promote persistence of AD lesions by releasing toxins that function as superantigens and induce extensive T-cell activation. They further destroy  the skin barrier as well as induce IgE antibodies, with subse- quent degranulation of basophils and mast cells resulting in flare-ups and pruritus (100, 101). Therefore, reducing S. aureus colonization by controlling inflammation and improving bar- rier function are supposed to improve AD. Restoring the epithelial barrier using skin protective measures and anti- inflammatory therapy also results in reduced colonization  with S. aureus (102, 103). Upon application of emollients and wet wraps with antiseptics, a rapid resolution of acute AD exacer- bations in parallel with a decreased S. aureus colonization was observed (104). Furthermore, bathing with disinfectants has been shown to reduce S. aureus on the skin resulting in a sig- nificant reduction in AD severity (105). Both topical therapy and systemic antibiotic therapy are not necessary and therefore should not be recommended to achieve a reduction in bacterial colonization.  In  particular,  the  continuous  use  of antibiotics whether topical or systemic should be avoided to reduce the risk of bacterial resistance. In our opinion, exclusively severe bacterial superinfection of eczematous skin with oozing and yellow crusted lesions, which are more typical for AD in child- hood, may require systemic antibiotic therapy. In addition to S aureus, Streptococcus pyogenes was found to cause superin- fection of eczematous lesions, in particular in patients with uncontrolled AD (106).

 

Antiviral therapy

 

Eczema herpeticum is a widespread herpes simplex infection of inflamed skin in patients with AD associated with severe systemic symptoms. Patients with severe AD, untreated skin lesions, early disease onset, and high total serum IgE levels  are at high risk to develop eczema herpeticum (107). Patients present with an eruption of dome-shaped blisters and pus- tules, fever, malaise, and lymphadenopathy. Therefore,  eczema herpeticum should be treated without delay using systemic antiviral therapy, such as acyclovir (10, 11).

 

Antimycotics

 

In a subset of patients with AD, IgE- as well as T-cell-mediated autoimmune reactions to manganese superoxide dismutase (MnSOD) have been identified as trigger (108). Patients 

sensitized to human MnSOD were found to cross-react with structurally related fungal MnSOD derived from Malassezia species (109). Systemic ketoconazole has been shown to be effective in the treatment for atopic dermatitis with IgE-medi- ated hypersensitivity to yeasts (110). However, in most cases of yeast-triggered AD, mainly in the head-and-neck area, a topi- cal antimycotic therapy seems sufficient as it has been demon- strated for ciclopiroxolamine cream (110).

 

 

Vitamin D

 

Vitamin D deficiency has been associated with an increased risk to develop atopic diseases including AD (111–113). Vitamin D was shown to affect both the innate and the adaptive immune system (114), and thus, low vitamin D levels might contribute to the main features of AD such as defective skin barrier and chronic skin inflammation. Vitamin D stimulates antimicrobial peptide expression by endothelial cells; inhibits dendritic cell activation, antigen presentation, and cytokine production; and supports macrophages defending opportunis- tic infections (114). As most cells of the adaptive immune sys- tem express the vitamin D receptor, vitamin D exhibits broad effects, for example, it may inhibit T-cell proliferation, sup- press Th17 cell, but increase regulatory T-cell functions, and blocks B-cell proliferation and immunoglobulin production Interestingly, the cathelicidin gene is directly regulated by vitamin D binding to the vitamin D response element in the promotor region (115). Indeed, low vitamin D levels correlated with low serum cathelicidin levels in patients with AD (116), and supplementation with 4000 IU  per  day  vitamin  D  for  21 days was reported to increase the expression of antimicro- bial peptides in lesional AD skin (117), although vitamin D therapy failed to significantly change cathelicidin, human beta- defensin 3, IL-13 blood levels, and AD severity (118).

The results on vitamin D status and therapeutic effects of supplementation are controversial. Recent studies found simi- lar blood vitamin D levels in patients with AD and age- and sex-matching controls and an inverse correlation between eczema and vitamin D in the pediatric population (119, 120). However, AD patients with very low 25 (OH) D3 levels (4  and 15 ng/ml) profited from vitamin D supplementation for 3 months as assessed by a significant  decrease in objective  and subjective SCORAD (119). Note that, pediatric patients with AD treated with vitamin D were found to have an increased risk of developing food allergy (120). As it is not clear whether vitamin D has a beneficial effect on AD and controlled multicenter studies are missing, we would not rec- ommend general vitamin D therapy for patients with AD.

 

Conclusion


The management of some moderate to severe forms of AD (SCORAD 18–40) resistant to topical treatment as  well  as that of severe forms (SCORAD >40) requires the use of sys- temic drug application. Unfortunately, besides cyclosporine, which is only approved in some European countries for this indication, none of the systemic immunosuppressive or immunomodulatory regimens suggested in national and inter- national guidelines is currently approved (Table 1). As the progress in our understanding of the genetics and pathophys- iology of AD is significantly growing in the last decade, the scientific community and the affected patients and their fami- lies are expecting some substantial new developments that  may be driven by the emerging era of personalized medicine. Considering the substantial socioeconomic burden of AD,  there is clear, unmet medical need which needs to be  addressed in the future by the pharmaceutical industry.

 

 

References

  1. Heinrich J, Hoelscher B, Frye C, Meyer I, Wjst M, Wichmann HE. Trends in preva- lence of atopic diseases and allergic sensiti- zation in children in Eastern Germany. Eur Respir J 2002;19:1040–1046.
  2. Schmitz R, Atzpodien K, Schlaud M. Prev- alence and risk factors of atopic diseases in German children and adolescents. Pediatr Allergy Immunol 2012;23:716–723.
  3. Ranci`ere F, Nikasinovic L, Bousquet J, Momas I. Onset and persistence of respira- tory/allergic symptoms in  preschoolers: New insights from the PARIS birth cohort. Allergy 2013;68:1158–1167.
  4. Ballardini N, Kull I, Lind T, Hallner E,Almqvist  C,  O€ stblom  E  et al.  Develop- ment and comorbidity of eczema, asthma and rhinitis to age 12 – data from the BAMSE birth cohort. Allergy 2012;67:537– 544.
  5. Wu€thrich B. Clinical aspects, epidemiology, and prognosis of atopic dermatitis. Ann Allergy Asthma Immunol 1999;83:464–470.
  6. Garmhausen D, Hagemann T, Bieber T, Dimitriou I, Fimmers R, Diepgen T et al. Characterization of different courses of ato- pic dermatitis in adolescent and adult patients. Allergy 2013;68:498–506.
  7. Thyssen JP, Johansen JD, Linneberg A, Menn´e T, Engkilde K. The association between contact sensitization and atopic disease by linkage of a clinical database and a nationwide patient registry. Allergy 2012;67:1157–1164.
  8. Schnuch A, Geier J, Lessmann H, Arnold R, Uter W. Surveillance of contact aller-

    gies: methods and results of the Informa- tion Network of Departments of Dermatology (IVDK). Allergy 2012;67:847– 857.

  9. Devillers AC, Oranje AP. Efficacy and safety of ‘wet-wrap’ dressings as an inter- vention treatment in children with severe and/or refractory atopic dermatitis: a criti- cal review of the literature. Br J Dermatol 2006;154:579–585.
  10. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C et al. Guide- lines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012;26:1045–1060.
  11. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C et al. Guide- lines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol 2012;26:1176–1193.
  12. Nomura I, Katsunuma T, Tomikawa M, Shibata A, Kawahara H, Ohya Y et al. Hypoproteinemia in severe childhood ato- pic dermatitis: a serious complication. Pedi- atr Allergy Immunol 2002;13:287–294.
  13. Al Shobaili HA. The impact of childhood atopic dermatitis on the patients’ family. Pediatr Dermatol 2010;27:618–623.
  14. Camfferman D, Kennedy JD, Gold M, Martin AJ, Lushington K. Eczema and sleep and its relationship to daytime func- tioning in children. Sleep Med Rev 2010;14:359–369.
  15. Rod NH, Kristensen TS, Lange P, Prescott E, Diderichsen F. Perceived stress and risk of adult-onset asthma and other atopicdisorders: a longitudinal cohort study.Allergy 2012;67:1408–1414.
  16. Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxon- omy and stratified medicine. Allergy 2012;67:1475–1482.
  17. Eyerich K, Novak N. Immunology of ato- pic eczema: overcoming the Th1/Th2 paradigm. Allergy 2013;68:974–982.
  18. Michel S, Busato F, Genuneit J, Pekkanen J, Dalphin JC, Riedler J et al. ; the PAS- TURE study group. Farm exposure and time trends in early childhood may influ- ence DNA methylation in genes related to asthma and allergy. Allergy 2013;68: 355–364.
  19. Dondi A, Ricci L, Neri I, Ricci G, Patrizi
    1. The switch from non-IgE-associated to IgE-associated atopic dermatitis occurs early in life. Allergy 2013;68:259–260.
  20. Barnes KC. An update on the genetics of atopic dermatitis: scratching the surface in 2009. J Allergy Clin Immunol 2010;125: 16–29.
  21. Casaca VI, Illi S, Klucker E, Ballenberger N, Schedel M, von Mutius E et al. STAT6 polymorphisms are associated with neona- tal regulatory T cells and cytokines and atopic diseases at 3 years. Allergy 2013;68:1249–1258.
  22. Palmer CN, Irvine AD, Terron-Kwiatkow- ski A, Zhao Y, Liao H, Lee SP et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic derma- titis. Nat Genet 2006;38:441–446
  23. Thyssen JP, Linneberg A, Johansen JD,Carlsen BC,  Zachariae C,  Meldgaard Met al. Atopic diseases by filaggrin mutations and birth year. Allergy 2012;67:705–708.
  24. Di WL, Hennekam RC, Callard RE, Harper JI. A heterozygous null mutation combined with the G1258A polymorphism of SPINK5 causes impaired LEKTI function and abnormal expression of skin barrier pro- teins. Br J Dermatol 2009;16:404–412.
  25. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T et al. Endogenous antimicrobial peptides and  skin  infections in atopic dermatitis. N Engl J Med 2002;347:1151–1160.
  26. Bieber T. Many ways lead to Rome: a glance at the multiple immunological path- ways underlying atopic dermatitis. Allergy 2013;68:957–958.
  27. Simon HU. Allergic inflammation: focus on eosinophils. Allergy 2013;68:823–824.
  28. Herrmann N, Koch S, Leib N, Bedorf J, Wilms H, Schnautz S et al. TLR2 down- regulates FceRI and its transcription factor PU.1 in human Langerhans cells. Allergy 2013;68:621–628.
  29. Morshed M, Yousefi S, Sto€ckle C, Simon HU, Simon D. Thymic stromal lympho- poietin stimulates the formation of eosino- phil extracellular traps. Allergy 2012;67:1127–1137.
  30. Ohno T, Morita H, Arae K, Matsumoto K, Nakae S. Interleukin-33 in allergy. Allergy 2012;67:1203–1214.
  31. Howell MD, Boguniewicz M, Pastore S, Novak N, Bieber T, Girolomoni G et al. Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol 2006;121:332–338.
  32. Gschwandtner M, Mildner M, Mlitz V, Gruber F, Eckhart L, Werfel T et al. Hista- mine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model. Allergy 2013;68:37–47.
  33. Simon D, Kernland Lang K. Atopic dermatitis: from new pathogenic insights toward a barrier-restoring and anti-inflam- matory therapy. Curr Opin Pediatr 2011;23:647–652.
  34. Simon D. Systemic therapy of atopic der- matitis in children and adults. Curr Probl Dermatol 2011;41:156–164.
  35. Galli E, Chini L, Moschese V, Paone F, Menichelli A, Fraioli G et al. Methylpred- nisolone bolus: a novel therapy for severe atopic dermatitis. Acta Paediatr 1994;83:315–317.
  36. Schmitt J, Sch€akel K, Fo€lster-Holst R, Bauer A, Oertel R, Augustin M et al. Pred- nisolone versus ciclosporin for severe adult eczema. An investigator-initiated double- blind placebo-controlled multicentre  trial. Br J Dermatol 2010;162:661–668.
  37. Salek MS, Finlay AY, Luscombe DK, Allen BR, Berth-Jones J, Camp RD et al. Cyclo- sporin greatly improves the quality of life of adults with severe atopic dermatitis. A ran- domized, double-blind, placebo-controlled trial. Br J Dermatol 1993;129:422–430.
  38. van Joost T, Heule F, Korstanje M, van den Broek MJ, Stenveld HJ, van Vloten WA. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol 1994;130:634–640.
  39. Berth-Jones J, Finlay AY, Zaki I, Tan B, Goodyear H, Lewis-Jones S et al. Cyclo- sporine in severe childhood atopic dermati- tis: a multicenter study. J Am Acad Dermatol 1996;34:1016–1021.
  40. Schmitt J, Schmitt N, Meurer M.  Cyclospo- rin in the treatment of patients with atopic eczema - a systematic review and meta- analysis. J Eur Acad Dermatol Venereol 2007;21:606–619.
  41. Mrowietz U, Klein CE, Reich K, Rosen- bach T, Ruzicka T, Sebastian M et al. Cyclosporine therapy in dermatology. J Dtsch Dermatol Ges 2009;7:474–479.
  42. Buckley DA, Baldwin P, Rogers S. The use   of azathioprine in  severe  adult  atopic eczema. J Eur Acad Dermatol Venereol 1998;11:137–140.
  43. Kuanprasert N, Herbert O, Barnetson RS. Clinical improvement and significant reduc- tion of total serum IgE in patients suffering from severe atopic dermatitis treated with oral azathioprine. Australas J Dermatol 2002;43:125–127.
  44. Hughes R, Collins P, Rogers S. Further experience of using azathioprine in the treatment of severe atopic dermatitis. Clin Exp Dermatol 2008;33:710–711.
  45. Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I et al. Azathioprine in severe adult atopic dermatitis: a double- blind, placebo-controlled, crossover  trial. Br J Dermatol 2002;147:324–330.
  46. Hon KL, Ching  GK,  Leung  TF,  Chow CM, Lee KK, Ng PC. Efficacy and tolera- bility at 3 and 6 months following use of azathioprine for recalcitrant atopic dermati- tis in children and young adults. J Derma- tolog Treat 2009;20:141–145.
  47. Murphy LA, Atherton DJ.  Azathioprine as a treatment for severe atopic eczema in children with a partial thiopurine methyl transferase (TPMT) deficiency. Pediatr Dermatol 2003;20:531–534.
  48. Meggitt SJ, Gray JC, Reynolds NJ. Azathi- oprine dosed by thiopurine methyltransfer- ase activity for moderate-to-severe atopic eczema: a double-blind, randomised con- trolled trial. Lancet 2006;367:839–846.
  49. Grundmann-Kollmann M, Korting HC, Behrens S, Leiter U, Kr€ahn G, Kaufmann R et al. Successful treatment of severerefractory atopic dermatitis with mycophen- olate mofetil. Br J Dermatol 1999;141:175– 176.
  50. Grundmann-Kollmann M, Podda M, Och- sendorf F, Boehncke WH, Kaufmann R, Zollner TM. Mycophenolate mofetil is effective in the treatment of atopic dermati- tis. Arch Dermatol 2001;137:870–873.
  51. Murray ML, Cohen JB. Mycophenolate mofetil therapy for moderate to severe ato- pic dermatitis. Clin Exp Dermatol 2007;32:23–27.
  52. Benez A, Fierlbeck G. Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil. Br J Dermatol 2001;144:638–639.
  53. Heller M, Shin HT, Orlow SJ, Schaffer JV. Mycophenolate mofetil for severe child- hood atopic dermatitis: experience in 14 patients. Br J Dermatol 2007;157:127–132.
  54. Neuber K, Schwartz I, Itschert G, Dieck AT. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol 2000;143:385–391.
  55. Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel- Koomen CA. Enteric-coated mycopheno- late sodium versus cyclosporin A as long- term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 2011;64:1074– 1084.
  56. Hantash B, Fiorentino D. Liver enzyme abnormalities in patients with atopic der- matitis treated with mycophenolate mofetil. Arch Dermatol 2006;142:109–110.
  57. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of methotrexate for moderate-to- severe adult atopic eczema. Br J Dermatol 2007;156:346–351.
  58. Goujon C, B´erard F, Dahel K, Guillot I,Hennino A, Nosbaum A et al.  Methotrex- ate for the treatment of adult atopic derma- titis. Eur J Dermatol 2006;16:155–158.
  59. Lyakhovitsky A, Barzilai A, Heyman R, Baum S, Amichai B, Solomon M et al. Low-dose methotrexate treatment for mod- erate-to-severe atopic dermatitis in adults. J Eur Acad Dermatol Venereol 2010;24:434– 439.
  60. El-Khalawany MA, Hassan H, Shaaban D, Ghonaim N, Eassa B. Methotrexate versus cyclosporine in the treatment of severe ato- pic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr 2013;172:351–356.
  61. Ruzicka T, Lynde CW, Jemec GB, Diepgen T, Berth-Jones J, Coenraads PJ et al. Effi- cacy and safety of oral alitretinoin (9-cis retinoic acid) in patients  with  severe chronic hand eczema refractory to topical corticosteroids: results of a randomizeddouble-blind, placebo-controlled, multicen- tre trial. Br J Dermatol 2008;158:808–817.
  62. Diepgen TL, Pfarr E, Zimmermann T. Effi- cacy and tolerability of alitretinoin for chronic hand eczema under daily practice conditions: results of the TOCCATA open study comprising 680 patients. Acta Derm Venereol 2012;92:251–255.
  63. Grahovac M, Molin S, Prinz JC, Ruzicka T, Wollenberg A. Treatment of atopic eczema with oral alitretinoin. Br J Derma- tol 2010;162:217–218.
  64. Kimata H. High dose gammaglobulin treat- ment for atopic dermatitis. Arch Dis Child 1994;70:335–336.
  65. Jolles S, Sewell C, Webster D, Ryan A, He- elan B, Waite A et al. Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts. Acta Derm Venereol 2003;83:433–437.
  66. Jolles S, Hughes J, Rustin M. The treat- ment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature. Br J Dermatol 2000;142:551–554.
  67. Wakim M, Alazard M, Yajima A, Speights D, Saxon A, Stiehm ER. High dose intra- venous immunoglobulin in atopic dermati- tis and hyper-IgE syndrome. Ann Allergy Asthma Immunol 1998;81:153–158.
  68. Paul C, Lahfa M, Bachelez H, Chevret S, Dubertret L. A randomized controlled eval- uator-blinded trial of intravenous immuno- globulin in adults with severe atopic dermatitis. Br J Dermatol 2002;147:518–522.
  69. Huang JL, Lee WY, Chen LC, Kuo ML, Hsieh KH. Changes of serum levels of interleukin-2, intercellular adhesion mole- cule-1, endothelial leukocyte adhesion mol- ecule-1 and Th1 and Th2 cell in severe atopic dermatitis after intravenous immu- noglobulin therapy. Ann Allergy Asthma Immunol 2000;84:345–352.
  70. Ozen A, Baris S, Karakoc Aydiner E, Yucelten D, Nadir Bahceciler N. Experi- ence with intravenous immunoglobulin in severe childhood atopic dermatitis. Allergol Immunopathol (Madr) 2012;40:131–133.
  71. Turner PJ, Kakakios A, Wong LC, Wong M, Campbell DE. Intravenous immuno- globulin to treat severe atopic dermatitis in children: a case series. Pediatr Dermatol 2012;29:177–1781.
  72. Panahi Y, Davoudi SM, Madanchi N, Abolhasani E. Recombinant human inter- feron gamma (Gamma Immunex) in treat- ment of atopic dermatitis. Clin Exp Med 2012;12:241–245.
  73. Boguniewicz M, Jaffe HS, Izu A, Sullivan MJ, York D, Geha RS et al. Recombinant gamma interferon in treatment of patientswith atopic dermatitis and elevated IgE lev- els. Am J Med 1990;88:365–370.
  74. Hanifin JM, Schneider LC,  Leung  DY, Ellis CN, Jaffe HS, Izu AE et al. Recombi- nant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993;28:189–197.
  75. Stevens SR, Hanifin JM, Hamilton T, Tofte SJ, Cooper KD. Long-term  effectiveness and safety of recombinant human  inter- feron gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 1998;134:799–804.
  76. Schneider LC, Baz Z, Zarcone C, Zurakow- ski D. Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis. Ann Allergy Asthma Immunol 1998;80:263–268.
  77. Simon D, Ho€sli S, Kostylina G, Yawalkar
  78. N, Simon HU. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008;121:122–128.

  79. Sediv´a A, Kayserov´a J, Vernerov´a E, Po- louckov´a A, Capkov´a S, Sp´ısek R et al. Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol 2008;121:1515–1516.
  80. Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J et al. Anti-IL-5 recombinant humanized monoclonal anti- body (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005;60:693–696.
  81. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A et al. Me- polizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973–984.
  82. Nair P, Pizzichini MM, Kjarsgaard M, In- man MD, Efthimiadis A, Pizzichini E et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985–993.
  83. Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels.  J Allergy Clin Immunol 2007;120:1223–1225.
  84. Incorvaia C, Pravettoni C, Mauro  M, Yacoub MR, Tarantini  F,  Riario-Sforza GG. Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis. Monaldi Arch Chest Dis 2008;69:78–80.
  85. Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 2010;8:990– 998.
  86. Hotze M, Baurecht H, Rodr´ıguez E, Chap-man-Rothe N, Ollert M, Fo€lster-Holst R et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-typefilaggrin status and higher serum levels of phosphatidylcholines. Allergy 2014;69:132–135.
  87. Toledo F, Silvestre JF, Mun~oz C. Com- bined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis. Report of four cases.J Eur Acad Dermatol Venereol2012;26:1325–1327.
  88. S´anchez-Ramo´n S, Egu´ıluz-Gracia I, Rodr´ıguez-Mazariego ME, Paravisini A, Zubeldia-Ortun~o JM, Gil-Herrera J et al. Sequential combined therapy with oma- lizumab and rituximab: a new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol 2013;23:190–196.
  89. Jacobi A, Antoni C, Manger B, Schuler G, Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005;52:522–526.
  90. Buka RL, Resh B, Roberts B, Cunningham BB, Friedlander S. Etanercept is minimally effective in 2 children with  atopic  dermati- tis. J Am Acad Dermatol 2005;53:358–359.
  91. Ruiz-Villaverde R, Gal´an-Gutierrez M. Exacerbation of atopic dermatitis in a patient treated with infliximab. Actas Dermosifiliogr 2012;103:743–746.
  92. Navarini AA, French LE, Hofbauer GF. Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J Allergy Clin Immunol 2011;128:1128–1130.
  93. Novak N, Simon D. Atopic dermatitis  - from new pathophysiologic insights to indi- vidualized therapy. Allergy 2011;66:830– 839.
  94. Ohsawa Y, Hirasawa N. The antagonism of histamine H1 and H4 receptors amelio- rates chronic allergic dermatitis via anti- pruritic and anti-inflammatory effects in NC/Nga mice. Allergy 2012;67:1014–1022.
  95. Kasperkiewicz M, Schmidt E, Frambach Y, Rose C, Meier M, Nitschke M et al. Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study. J Allergy Clin Immunol 2011;127:267–270.
  96. Werfel T, Breuer K, Ru´eff F, Przybilla B,Worm M, Grewe M et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, ran- domized, dose-response study. Allergy 2006;61:202–205.
  97. Novak N, Bieber T, Hoffmann M, Fo€lster-Holst R, Homey B, Werfel T et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymer- ized mite extract in atopic dermatitis. J Allergy Clin Immunol 2012;130:925–931.Cadario G, Galluccio AG, Pezza M, Appi- no A, Milani M, Pecora S et al. Sublingualimmunotherapy efficacy in patients with atopic dermatitis and house dust mites sen- sitivity: a prospective pilot study. Curr Med Res Opin 2007;23:2503–2506.
  98. Novak N, Thaci D, Hoffmann M, Fo€lster-Holst R, Biedermann T, Homey B et al. Subcutaneous immunotherapy with a depigmented polymerized birch pollen extract–a new therapeutic option for patients with atopic dermatitis. Int Arch Allergy Immunol 2011;155:252–256.
  99. Bae JM, Choi YY, Park CO, Chung  KY, Lee KH. Efficacy of allergen-specific immu- notherapy for atopic dermatitis: a system- atic review and meta-analysis  of randomized controlled trials. J Allergy Clin Immunol 2013;132:110–117.
  100. Krysko O, Maes T, Plantinga M, Holtap- pels G, Imiru R, Vandenabeele P et al. The adjuvant-like activity of staphylococcal enterotoxin B in a murine asthma model is independent of IL-1R signaling. Allergy 2013;68:446–453.
  101. Kim MR, Hong SW, Choi EB, Lee WH, Kim YS, Jeon SG et al. Staphylococcus aureus-derived extracellular vesicles induce neutrophilic pulmonary inflammation via both Th1 and Th17 cell responses. Allergy 2012;67:1271–1281.
  102. Stalder JF, Fleury  M,  Sourisse  M,  Rostin M, Pheline F, Litoux P. Local steroid ther-  apy and bacterial skin flora in atopic der- matitis. Br J Dermatol 1994;131:536–540.
  103. Gong JQ, Lin L, Lin T, Hao  F, Zeng  FQ, Bi ZG et al. Skin colonization by Staphylo- coccus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol 2006;155:680–687.
  104. Abeck D, Brockow K, Mempel M, Fesq H, Ring J. Treatment of acute exacerbated ato- pic eczema with emollient-antiseptic prepa- rations using the “wet wrap” (“wet pajama”) technique. Hautarzt 1999;50:418–421.
  105. Huang JT, Abrams M, Tlougan B, Rade- maker A, Paller AS. Treatment of Staphy- lococcus aureus colonization in atopic dermatitis decreases disease severity. Pediat- rics 2009;123:e808–e814.
  106. Hayakawa K, Hirahara K, Fukuda T, Okazaki M, Shiohara T. Risk factors for severe impetiginized atopic dermatitis in Japan and assessment of its microbiological features. Clin Exp Dermatol 2009;34:e63– e65.
  107. Wollenberg A, Zoch C, Wetzel S, Plewig G, Przybilla B. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol 2003;49:198–205.
  108. Schmid-Grendelmeier P, Flu€ckiger S, Disch R, Trautmann A, Wu€thrich B, Blaser Ket al. IgE-mediated and T cell-mediated au- toimmunity against manganese superoxide dismutase in atopic dermatitis. J  Allergy Clin Immunol 2005;115:1068–1075.
  109. Lintu P, Savolainen J, Kortekangas-Savo- lainen O, Kalimo K. Systemic ketoconazole is an effective treatment of atopic dermati- tis with IgE-mediated hypersensitivity to yeasts. Allergy 2001;56:512–517.
  110. Mayser P, Kupfer J, Nemetz D, Sch€afer U, Nilles M, Hort W et al. Treatment of head and neck dermatitis with ciclopiroxolamine cream–results of a double-blind, placebo- controlled study. Skin Pharmacol Physiol 2006;19:153–158.
  111. Weisse K, Winkler S, Hirche  F,  Herberth G, Hinz D, Bauer M et al. Maternal and newborn vitamin D status  and  its  impact on food allergy development in the German LINA cohort study. Allergy 2013;68:220– 228.
  112. Querfeld U, Keil T, Beyer K, Stock P, Pilz S, M€arz W et al. Vitamin D in early life: good or bad for food allergies? Allergy 2013;68:1081–1083.
  113. Frieri M, Valluri A. Vitamin D deficiency as a risk factor for allergic disorders and

    immune mechanisms. Allergy Asthma Proc

    2011;32:438–444.

  114. Benson AA, Toh JA, Vernon N, Jariwala SP. The role of vitamin D in the immuno- pathogenesis of allergic skin diseases. Allergy 2012;67:296–301.
  115. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004;173:2909– 2912.
  116. Kanda N, Hau CS, Tada Y, Sato S, Watanabe S. Decreased serum LL-37 and vitamin D3 levels in atopic dermatitis: rela- tionship between IL-31 and oncostatin M. Allergy 2012;67:804–812.
  117. Hata TR, Kotol P, Jackson M, Nguyen M, Paik A, Udall D et al. Administration of oral vitamin D induces cathelicidin produc- tion in atopic individuals. J Allergy Clin Immunol 2008;122:829–831.
  118. Hata TR, Audish D, Kotol P, Coda A, Kabigting F, Miller J et al. A randomized controlled double-blind investigation of the effects of vitamin D dietary supplementa- tion in subjects with atopic dermatitis.J Eur Acad Dermatol Venereol 2013, doi: 10.1111/jdv.12176.
  119. Samochocki Z, Bogaczewicz J, Jez- iorkowska R, Sysa-Jezdrzejowska A, Glin´ska O, Karczmarewicz E et al. VitaminD effects in atopic dermatitis. J Am Acad Dermatol 2013;69:238–244.
  120. Heimbeck I, Wjst M, Apfelbacher CJ. Low vitamin D serum level is inversely associ- ated with eczema in children and adoles- cents in Germany. Allergy 2013;68:906– 910.
  121. Norizoe C, Akiyama N, Segawa T, Tachimoto H, Mezawa H, Ida H et al. Increased food allergy with vitamin D: a randomized, double-blind, placebo- controlled trial. Pediatr Int 2013,doi: 10.1111/ped.12207.

 

Fișiere atașate

pdf

Comentarii